Loading...

ValiRx

DB:EAJD
Snowflake Description

Adequate balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
EAJD
DB
£4M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

ValiRx plc, a biotechnology oncology focused company, engages in developing novel treatments for cancer and associated biomarkers in the United Kingdom. The last earnings update was 205 days ago. More info.


Add to Portfolio Compare Print
  • ValiRx has significant price volatility in the past 3 months.
EAJD Share Price and Events
7 Day Returns
0%
DB:EAJD
0.3%
DE Biotechs
2.3%
DE Market
1 Year Returns
-
DB:EAJD
-7.9%
DE Biotechs
-7.2%
DE Market
EAJD Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
ValiRx (EAJD) 0% -40% -60% - - -
DE Biotechs 0.3% 3.1% -6.5% -7.9% 43.5% 7.6%
DE Market 2.3% 3.1% 8.8% -7.2% 9.3% 12.3%
1 Year Return vs Industry and Market
  • No trading data on EAJD.
  • No trading data on EAJD.
Price Volatility
EAJD
Industry
5yr Volatility vs Market
Related Companies

EAJD Value

 Is ValiRx undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for ValiRx. This is due to cash flow or dividend data being unavailable. The share price is €0.006.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for ValiRx's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are ValiRx's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:EAJD PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in GBP £-0.01
AIM:VAL Share Price ** AIM (2019-04-17) in GBP £0.01
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 23.37x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.43x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of ValiRx.

DB:EAJD PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AIM:VAL Share Price ÷ EPS (both in GBP)

= 0.01 ÷ -0.01

-0.5x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ValiRx is loss making, we can't compare its value to the Europe Biotechs industry average.
  • ValiRx is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does ValiRx's expected growth come at a high price?
Raw Data
DB:EAJD PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.5x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
-10.1%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 272 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for ValiRx, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on ValiRx's assets?
Raw Data
DB:EAJD PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in GBP £0.01
AIM:VAL Share Price * AIM (2019-04-17) in GBP £0.01
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.89x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:EAJD PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AIM:VAL Share Price ÷ Book Value per Share (both in GBP)

= 0.01 ÷ 0.01

0.65x

* Primary Listing of ValiRx.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ValiRx is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess ValiRx's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. ValiRx has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

EAJD Future Performance

 How is ValiRx expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-10.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is ValiRx expected to grow at an attractive rate?
  • Unable to compare ValiRx's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare ValiRx's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare ValiRx's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:EAJD Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:EAJD Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts -10.1%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:EAJD Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in GBP Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:EAJD Future Estimates Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 0 -4 -4 1
2019-12-31 0 -4 -4 1
2018-12-31 0 -3 -3 1
DB:EAJD Past Financials Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income *
2018-06-30 -3 -3
2018-03-31 -3 -3
2017-12-31 -2 -3
2017-09-30 -3 -4
2017-06-30 -4 -5
2017-03-31 -4 -5
2016-12-31 -4 -5
2016-06-30 0 -2 -3
2016-03-31 0 -3 -2
2015-12-31 -3 -2
2015-09-30 0 -3 -3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • ValiRx is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if ValiRx is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:EAJD Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from ValiRx Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:EAJD Future Estimates Data
Date (Data in GBP Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31 -0.01 -0.01 -0.01 1.00
2019-12-31 -0.01 -0.01 -0.01 1.00
2018-12-31 -0.01 -0.01 -0.01 1.00
DB:EAJD Past Financials Data
Date (Data in GBP Millions) EPS *
2018-06-30 -0.01
2018-03-31 -0.01
2017-12-31 -0.02
2017-09-30 -0.03
2017-06-30 -0.05
2017-03-31 -0.06
2016-12-31 -0.09
2016-06-30 -0.06
2016-03-31 -0.06
2015-12-31 -0.06
2015-09-30 -0.09

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if ValiRx will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess ValiRx's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
ValiRx has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

EAJD Past Performance

  How has ValiRx performed over the past 5 years?

  • ValiRx's last earnings update was 205 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare ValiRx's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • ValiRx does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare ValiRx's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare ValiRx's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
ValiRx's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from ValiRx Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:EAJD Past Revenue, Cash Flow and Net Income Data
Date (Data in GBP Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 -3.13 1.96 1.88
2018-03-31 -3.08 1.71 1.81
2017-12-31 -3.02 1.47 1.75
2017-09-30 -3.75 1.53 2.10
2017-06-30 -4.68 1.80 2.46
2017-03-31 -4.81 1.80 2.42
2016-12-31 -4.93 1.79 2.38
2016-06-30 -0.15 -2.50 1.13 1.32
2016-03-31 -0.08 -2.15 1.25 1.43
2015-12-31 -1.79 1.36 1.54
2015-09-30 0.13 -2.65 1.88 1.75
2015-06-30 0.18 -3.19 2.07 1.96
2015-03-31 0.13 -3.17 1.83 1.87
2014-12-31 0.09 -3.16 1.60 1.77
2014-09-30 0.08 -2.79 1.40 1.55
2014-06-30 0.08 -2.41 1.20 1.32
2014-03-31 0.10 -2.50 1.28 1.47
2013-12-31 0.12 -2.60 1.36 1.62
2013-09-30 0.14 -2.59 1.41 1.53
2013-06-30 0.16 -2.57 1.46 1.44
2013-03-31 0.19 -2.37 1.47 1.23
2012-12-31 0.22 -2.16 1.48 1.01
2012-09-30 0.21 -2.01 1.43 0.91
2012-06-30 0.19 -1.86 1.38 0.81

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if ValiRx has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if ValiRx has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if ValiRx improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess ValiRx's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
ValiRx has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

EAJD Health

 How is ValiRx's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up ValiRx's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • ValiRx is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • ValiRx has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of ValiRx's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • ValiRx has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from ValiRx Company Filings, last reported 9 months ago.

DB:EAJD Past Debt and Equity Data
Date (Data in GBP Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 3.82 0.00 0.59
2018-03-31 3.82 0.00 0.59
2017-12-31 3.15 0.43 0.70
2017-09-30 3.15 0.43 0.70
2017-06-30 1.99 1.13 0.38
2017-03-31 1.99 1.13 0.38
2016-12-31 2.37 1.29 0.56
2016-06-30 3.41 0.00 0.57
2016-03-31 3.41 0.00 0.57
2015-12-31 4.53 0.00 0.23
2015-09-30 4.53 0.00 0.23
2015-06-30 3.07 0.00 0.39
2015-03-31 3.07 0.00 0.39
2014-12-31 2.79 0.00 0.45
2014-09-30 2.79 0.00 0.45
2014-06-30 4.11 0.00 0.76
2014-03-31 4.11 0.00 0.76
2013-12-31 3.23 0.00 0.96
2013-09-30 3.23 0.00 0.96
2013-06-30 3.43 0.00 1.17
2013-03-31 3.43 0.00 1.17
2012-12-31 5.04 0.00 2.26
2012-09-30 5.04 0.00 2.26
2012-06-30 4.48 0.00 1.38
  • ValiRx has no debt.
  • ValiRx had no debt 5 years ago.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • ValiRx has less than a year of cash runway based on current free cash flow.
  • ValiRx has less than a year of cash runway if free cash flow continues to grow at historical rates of 1.9% each year.
X
Financial health checks
We assess ValiRx's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. ValiRx has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

EAJD Dividends

 What is ValiRx's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from ValiRx dividends.
If you bought €2,000 of ValiRx shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate ValiRx's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate ValiRx's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:EAJD Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:EAJD Future Dividends Estimate Data
Date (Data in £) Dividend per Share (annual) Avg. No. Analysts
2020-12-31
2019-12-31
2018-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as ValiRx has not reported any payouts.
  • Unable to verify if ValiRx's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of ValiRx's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as ValiRx has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess ValiRx's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can ValiRx afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. ValiRx has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

EAJD Management

 What is the CEO of ValiRx's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Satu Vainikka
COMPENSATION £192,240
AGE 51
CEO Bio

Dr. Satu Vainikka, Ph.D., MBA, serves as Chief Executive Officer at ValiRx plc. Dr. Vainikka is associated with ValiRx Finland Oy. She has been Director at ValiRx plc since October 2006. She serves as Director at Belgian Volition SA. She has been Director at Standard Capital Corp since October 06, 2011. She served as Director at VolitionRx Limited since October 06, 2011 until May 15, 2013. Dr. Vainikka holds PhD in molecular biology and Oncology from Helsingin yliopisto universoty in 1996 and MBA from Imperial College Business School in 2000.

CEO Compensation
  • Satu's compensation has increased whilst company is loss making.
  • Satu's remuneration is about average for companies of similar size in Germany.
Management Team

Satu Vainikka

TITLE
Founding Director & CEO
COMPENSATION
£192K
AGE
51

James Desler

TITLE
Founding Director & CFO
COMPENSATION
£82K
AGE
62

George Morris

TITLE
Founding Director & COO
COMPENSATION
£156K
AGE
62

Kevin Alexander

TITLE
Secretary & Non-Executive Director
COMPENSATION
£26K
AGE
62

Tarquin Edwards

TITLE
Head of Investor Relations & Communications
Board of Directors Tenure

Average tenure and age of the ValiRx board of directors in years:

9
Average Tenure
62
Average Age
  • The tenure for the ValiRx board of directors is about average.
Board of Directors

Oliver de Giorgio-Miller

TITLE
Senior Independent Non-Executive Chairman
COMPENSATION
£36K
AGE
67
TENURE
5.5 yrs

Satu Vainikka

TITLE
Founding Director & CEO
COMPENSATION
£192K
AGE
51
TENURE
12.5 yrs

James Desler

TITLE
Founding Director & CFO
COMPENSATION
£82K
AGE
62
TENURE
12.9 yrs

George Morris

TITLE
Founding Director & COO
COMPENSATION
£156K
AGE
62
TENURE
12.5 yrs

Kevin Alexander

TITLE
Secretary & Non-Executive Director
COMPENSATION
£26K
AGE
62
TENURE
12.5 yrs

Seppo Mäkinen

TITLE
Member of Advisory Board
COMPENSATION
£11K
AGE
66
TENURE
1.8 yrs

Richard Harbottle

TITLE
Member of Scientific Advisory Board

Alan Calvert

TITLE
Member of Scientific Advisory Board

Ajay Agrawal

TITLE
Member of Advisory Board
AGE
53
TENURE
1.8 yrs

Andrew King

TITLE
Member of Advisory Board
TENURE
1.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
18. Dec 18 Buy Satu Vainikka Individual 18. Dec 18 18. Dec 18 1,333,333 €0.01 €11,119
18. Dec 18 Buy George Morris Individual 18. Dec 18 18. Dec 18 1,333,333 €0.01 €11,119
18. Dec 18 Buy Oliver de Giorgio-Miller Individual 18. Dec 18 18. Dec 18 1,333,333 €0.01 €11,119
18. Dec 18 Buy James Desler Individual 18. Dec 18 18. Dec 18 1,333,333 €0.01 €11,119
X
Management checks
We assess ValiRx's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. ValiRx has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

EAJD News

Simply Wall St News

EAJD Company Info

Description

ValiRx plc, a biotechnology oncology focused company, engages in developing novel treatments for cancer and associated biomarkers in the United Kingdom. Its proprietary GeneICE technology enables the selective silencing of specific genes by targeted histone deacetylation leading to chromatin condensation. The company’s lead drug candidates include VAL201, an anti-cancer therapeutic that is in Phase I/II trials for the treatment of prostate cancer and other indications of hormone induced unregulated growth, including endometriosis; VAL301, a reformulation of VAL201, which is in pre-clinical development for the non-invasive and better tolerated treatment of endometriosis; and VAL401, a reformulation of generic drug Risperidone, which has completed Phase II clinical trials for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL101, a therapeutic based on GeneICE platform that acts to target and switch off the Bcl-2 gene, a protein that is implicated carcinomas. It has licensing collaborations with Imperial Innovations Group plc, Cancer Research UK, and University College London Hospital. ValiRx plc was incorporated in 2000 and is based in London, the United Kingdom.

Details
Name: ValiRx plc
EAJD
Exchange: DB
Founded: 2000
£4,326,928
681,629,382
Website: http://www.valirx.com
Address: ValiRx plc
16 Upper Woburn Place,
3rd Floor,
London,
Greater London, WC1H 0BS,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AIM VAL Ordinary Shares London Stock Exchange AIM Market GB GBP 03. Oct 2006
DB EAJD Ordinary Shares Deutsche Boerse AG DE EUR 03. Oct 2006
MUN EAJD Ordinary Shares Boerse Muenchen DE EUR 03. Oct 2006
Number of employees
Current staff
Staff numbers
12
ValiRx employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 00:29
End of day share price update: 2019/04/17 00:00
Last estimates confirmation: 2018/11/01
Last earnings filing: 2018/09/25
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.